Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Healthcare Sector Analysis

UpdatedOct 01, 2025
DataAggregated Company Financials
Companies218
  • 7D1.7%
  • 3M11.1%
  • 1Y4.4%
  • YTD19.4%

Over the last 7 days, the Healthcare industry has remained flat, although notably PharmaEssentia gained 7.7%. In line with that, the industry has also been flat over the past 12 months. Earnings are forecast to grow by 98% annually.

Sector Valuation and Performance

Has the Taiwanese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Oct 2025NT$1.8tNT$266.0bNT$8.2b22.6x220x6.8x
Sat, 30 Aug 2025NT$1.8tNT$266.1bNT$9.2b21.8x195.1x6.7x
Mon, 28 Jul 2025NT$1.7tNT$262.1bNT$16.5b21.2x100.1x6.3x
Wed, 25 Jun 2025NT$1.6tNT$260.9bNT$16.3b19.7x98.7x6.2x
Fri, 23 May 2025NT$1.5tNT$260.7bNT$16.4b19.8x91.3x5.7x
Sun, 20 Apr 2025NT$1.4tNT$254.7bNT$12.1b20.1x114.4x5.4x
Tue, 18 Mar 2025NT$1.6tNT$254.2bNT$12.0b23.7x134.1x6.4x
Thu, 13 Feb 2025NT$1.7tNT$246.5bNT$8.4b23.3x197x6.7x
Sat, 11 Jan 2025NT$1.6tNT$245.2bNT$8.6b22.1x180.7x6.3x
Mon, 09 Dec 2024NT$1.5tNT$244.9bNT$8.8b22.1x171.9x6.2x
Wed, 06 Nov 2024NT$1.5tNT$236.7bNT$6.9b25.5x223.1x6.5x
Fri, 04 Oct 2024NT$1.6tNT$236.4bNT$6.8b24.7x233.9x6.7x
Sun, 01 Sep 2024NT$1.6tNT$236.6bNT$6.7b26.3x244.6x6.9x
Tue, 30 Jul 2024NT$1.6tNT$229.1bNT$3.8b28.8x421.4x7x
Thu, 27 Jun 2024NT$1.6tNT$228.6bNT$3.9b27.8x402.4x6.9x
Sat, 25 May 2024NT$1.5tNT$228.7bNT$3.9b25.9x380.5x6.5x
Mon, 22 Apr 2024NT$1.4tNT$228.8bNT$4.5b26.2x311.3x6.1x
Wed, 20 Mar 2024NT$1.4tNT$228.1bNT$7.4b25.4x191.9x6.3x
Fri, 16 Feb 2024NT$1.4tNT$225.8bNT$6.5b25.5x216.7x6.2x
Sun, 14 Jan 2024NT$1.4tNT$224.9bNT$6.0b25x231.5x6.2x
Tue, 12 Dec 2023NT$1.4tNT$224.7bNT$5.9b25.2x239.3x6.2x
Thu, 09 Nov 2023NT$1.4tNT$225.3bNT$7.8b25.9x180.1x6.2x
Sat, 07 Oct 2023NT$1.4tNT$225.3bNT$8.3b25.5x166.3x6.1x
Mon, 04 Sep 2023NT$1.4tNT$225.2bNT$8.4b26x166.9x6.2x
Wed, 02 Aug 2023NT$1.4tNT$227.0bNT$11.4b24.4x124.8x6.3x
Fri, 30 Jun 2023NT$1.5tNT$226.5bNT$11.6b25.2x128x6.5x
Sun, 28 May 2023NT$1.4tNT$226.2bNT$14.0b22.9x101.6x6.3x
Tue, 25 Apr 2023NT$1.4tNT$219.9bNT$12.3b23.1x117.6x6.6x
Thu, 23 Mar 2023NT$1.4tNT$221.2bNT$14.0b21.1x99.4x6.3x
Sat, 18 Feb 2023NT$1.4tNT$214.7bNT$13.8b21.5x103.2x6.6x
Mon, 16 Jan 2023NT$1.3tNT$214.5bNT$13.8b19.7x92.4x6x
Wed, 14 Dec 2022NT$1.3tNT$214.5bNT$14.1b20.4x95x6.3x
Fri, 11 Nov 2022NT$1.2tNT$209.3bNT$11.4b17.8x103.3x5.6x
Sun, 09 Oct 2022NT$1.3tNT$207.4bNT$10.8b19.4x116.3x6x
Price to Earnings Ratio

116.3x


Total Market Cap: NT$1.3tTotal Earnings: NT$10.8bTotal Revenue: NT$207.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Healthcare Sector Price to Earnings3Y Average 182.9x202320242025
Current Industry PE
  • Investors are optimistic on the Taiwanese Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 220x which is higher than its 3-year average PE of 183x.
  • The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 8.6% per year over the last three years.
  • Meanwhile revenues for these companies have grown 8.7% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare sector?

TW Market-0.85%
Healthcare1.66%
Life Sciences9.86%
Biotech2.89%
Pharma1.41%
Medical Equipment0.23%
Healthcare Services-0.45%
Healthtech-7.10%
Industry PE
  • Investors are most optimistic about the Pharma industry which is trading above its 3-year average PE ratio of 66.4x.
    • Analysts are expecting annual earnings growth of 132.6%, which is higher than its past year's earnings growth of 5.4% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 133% over the next 5 years.
  • This is better than its past earnings growth rate of 5.4% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 21% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6446 PharmaEssentiaNT$552.006.4%
+NT$12.2b		-4.7%PE50.4x
1795 Lotus PharmaceuticalNT$263.0013.4%
+NT$8.2b		0.8%PE14.2x
6785 Alar PharmaceuticalsNT$282.0029.7%
+NT$4.3b		53.7%PS2664.4x
6589 EirGenixNT$73.7017.2%
+NT$3.3b		-16.6%PS23.3x
6620 Handa PharmaceuticalsNT$137.5016.5%
+NT$3.1b		88.6%PE34.7x

Latest News

6620
NT$137.50
Handa Pharmaceuticals
7D
16.5%
1Y
88.6%
6472
NT$694.00
Bora Pharmaceuticals
7D
2.4%
1Y
11.6%

US CDMO Expansion And Specialty Focus Will Strengthen Position

The consensus analyst price target for Bora Pharmaceuticals has been revised upward, primarily driven by a significant increase in the company's expected future P/E multiple, with the fair value rising from NT$847.46 to NT$872.67. What's in the News Bora Pharmaceuticals is making significant investments to expand manufacturing and packaging capabilities at its Maple Grove, Minnesota facility, acquired via the $210 million Upsher-Smith Laboratories deal in 2024.
4123
NT$36.69
Center Laboratories
7D
-6.2%
1Y
-23.5%
1795
NT$263.00
Lotus Pharmaceutical
7D
13.4%
1Y
0.8%

Alpha Choay Acquisition And New R&D Center Will Strengthen Southeast Asia Presence

The upward revision in Lotus Pharmaceutical's consensus price target reflects sharply improved revenue growth forecasts and a substantially lower future P/E, raising the fair value estimate from NT$322.40 to NT$346.00. Valuation Changes Summary of Valuation Changes for Lotus Pharmaceutical The Consensus Analyst Price Target has risen from NT$322.40 to NT$346.00.
7799
NT$622.00
Heron Neutron Medical
7D
-9.5%
1Y
n/a
6841
NT$73.10
Ever Fortune.AI
7D
-11.7%
1Y
-13.3%
6550
NT$36.05
Polaris Group
7D
-3.1%
1Y
-34.3%
6919
NT$185.50
Caliway Biopharmaceuticals
7D
-1.3%
1Y
224.9%
6712
NT$187.00
Ever Supreme Bio Technology
7D
6.3%
1Y
10.6%
1799
NT$52.90
Easywell Biomedicals
7D
16.3%
1Y
-45.6%
6589
NT$73.70
EirGenix
7D
17.2%
1Y
-16.6%
3218
NT$154.00
Universal Vision Biotechnology
7D
-4.3%
1Y
-39.8%
6446
NT$552.00
PharmaEssentia
7D
6.4%
1Y
-4.7%
6499
NT$90.20
Medeon Biodesign
7D
-6.3%
1Y
95.7%
6785
NT$282.00
Alar Pharmaceuticals
7D
29.7%
1Y
53.7%
6467
NT$167.50
Taho Pharmaceuticals
7D
-11.6%
1Y
n/a